ULT (−) | ULT (+) | ||||
sUA, mg/mL | sUA, mg/mL | ||||
≥8.0 | ≤5.0 | >5.0, ≤6.0 | >6.0, ≤7.0 | >7.0 | |
Asymptomatic hyperuricaemia | |||||
n=7049 | n=88 | n=249 | n=358 | n=526 | |
Time to first gout flare in period 2 | |||||
Median time (95% CI) | – | – | – | – | – |
HR (95% CI) versus ULT (−)* | – | 0.64 (0.32 to 1.29) | 0.45 (0.27 to 0.76) | 0.97 (0.71 to 1.32) | 1.29 (1.04 to 1.61) |
P value versus ULT (−)* | – | 0.216 | 0.002 | 0.839 | 0.022 |
Incidence rate of gout flare in period 2 | |||||
Incidence rate (95% CI)†, flares/person-year | 0.035 (0.024 to 0.051) | 0.023 (0.010 to 0.053) | 0.014 (0.008 to 0.027) | 0.032 (0.019 to 0.053) | 0.043 (0.027 to 0.068) |
RR (95% CI) versus ULT (−)† | – | 0.65 (0.31 to 1.39) | 0.40 (0.24 to 0.68) | 0.91 (0.64 to 1.31) | 1.23 (0.93 to 1.63) |
P value versus ULT (−)† | – | 0.269 | 0.001 | 0.624 | 0.141 |
Gout | |||||
n=107 | n=33 | n=68 | n=102 | n=201 | |
Time to first gout flare in period 2 | |||||
Median time (95% CI) | 158.3 (120.6 to –) | 127.6 (14.9 to –) | – (164.6 to –) | – (176.3 to –) | 125.6 (87.3 to 157.1) |
HR (95% CI) versus ULT (−)* | – | 1.22 (0.71 to 2.10) | 0.65 (0.40 to 1.05) | 0.76 (0.51 to 1.14) | 1.23 (0.89 to 1.70) |
P value versus ULT (−)* | – | 0.465 | 0.078 | 0.179 | 0.207 |
Incidence rate of gout flare in period 2 | |||||
Incidence rate (95% CI)†, flares/person-year | 0.298 (0.096 to 0.924) | 0.263 (0.077 to 0.894) | 0.162 (0.051 to 0.516) | 0.273 (0.091 to 0.823) | 0.286 (0.094 to 0.869) |
RR (95% CI) versus ULT (−)† | – | 0.88 (0.48 to 1.63) | 0.54 (0.33 to 0.91) | 0.92 (0.59 to 1.42) | 0.96 (0.66 to 1.39) |
P value versus ULT (−)† | – | 0.690 | 0.020 | 0.694 | 0.822 |
*Multivariable analysis using Cox proportional-hazards model. Sex, number of comorbidities of interest in period 1, and age, eGFR, and sUA control at the follow-up date were included in the model.
†Multivariable analysis using negative binomial regression model. Sex, number of comorbidities of interest in period 1, and age, eGFR, and sUA control at the follow-up date were included in the model.
RR, relative incidence rate; sUA, serum uric acid levels; ULT, urate-lowering therapy.